AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Samsung Bioepis’ legal challenge to patents on AbbVie’s blockbuster Humira is beginning in the UK Patent Court, which could pave the way for cheaper biosimilars to be marketed from 2018.

AbbVie’s executives, perhaps guided by previously slow biosimilar adoption in Europe, have forecast a drop of Humira sales in Europe of only around 18 to 20%, by the end of next year.

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of exclusivity (LOE) for its blockbuster drug Humira while simultaneously ...